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PATHOLOGY OF ALZHEIMER DISEASE 
Introduction
Neuropathological examination of the b.rain after au­
topsy of an Alzheimer disease (AD) patient will reveal a 
number of characteristic pathological changes comprising 
senile plaques, neurofibrillary tangles, congophilic angi­
opathy (CA) of the vessels, neuropil threads and neuronal 
cell loss. The amyloid (3 protein (A(3) is the major com­
ponent of both senile plaques and CA. Both lesions are 
found in the brains from patients with AD, Down syndrome 
or hereditary cerebral hemorrhage with amyloidosis - 
Dutch type (HCHWA-D).
Two major types of senile plaques have been identi­
fied: classic and diffuse senile plaques, which are both 
abundant in AD brains. It is suggested that diffuse senile 
plaques gradually transform into the fibril-containing 
classic senile plaques (1).
CA is found in both cortical and leptomeningeal ves­
sels of AD and Down syndrome brains. In HCHWA-D 
patients, severe cerebrovascular Ap deposition leads to 
small infarcts and to often fatal hemorrhages in the brains 
of these patients. A mutation at position 22 of the Ap 
sequence, substituting a glutamine for a glutamic acid (2), 
is directly related to the deposition of Ap in diffuse senile 
plaques and CA. Another type of A(3 deposition, dyshoric 
angiopathy (DA), is observed around cortical vessels and 
is characterized by the infiltration of fine radiating de­
posits of amyloid into the nearby neuropil, which sug­
gests a vascular origin. The incidcnce of this type of am­
yloid deposition is increased proportionally to the 
severity of CA (3) and is usually found in conjunction 
with amyloid deposition in pre-capillary arterioles.
Rather than presenting a complete overview of the 
pathological aspects of these lesions, in this review we 
will focus on data that support the hypothesis that in AD 
a different pathogenesis exists for either senile plaques 
or CA.
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Amyloid Protein
A/3 in Senile Plaques and in Congophilic Angiopathy: 
A (3 is a fragment of a large protein, designated as the 
amyloid precursor protein (APP), encoded by a gene on 
chromosome 21 (see [1] for a review of the cell biology 
of APP). The A(3 peptide that accumulates in AD brains 
is heterogeneous at its C-terminus, which results in pep­
tides of 39 to 43 amino acids long. Several studies have 
been published with regard to the exact length of A(3 in 
CA and senile plaques using chromatographic and mass 
spectrometry techniques or by immunohistochemistry us­
ing antibodies that specifically recognize either A(3N40 or 
A(3M2/43- Using these C-terminal-specific anti-A3 antibod­
ies, it was described that diffuse senile plaques in brains 
from normal individuals and AD patients only contained 
A-(31-42/43• Ap ,.40 was absent from, or present only in a mi­
nority of, diffuse senile plaques (4-6). Furthermore, in 
brains from young Down syndrome patients, HCHWA-D 
patients, and in the cerebellum of Down syndrome and 
AD patients, i.e. in conditions in which classic senile 
plaques are almost completely absent, the diffuse senile 
plaques were predominantly composed of ApM2/43 (6 , 7). 
In contrast, classic senile plaques contained both Ap^o 
and Ap1.42/43 and also shorter AP peptides, truncated at the 
N-terminus, and starting at residue 11 or 17 (5, 6 , 8).
The Ap content of CA differs from that of diffuse se­
nile plaques, but shows similarities to classic senile 
plaques. Immunohistochemical data indicated that CA in 
AD and HCHWA-D contained both A p M0 and A p i.42/43 
(5, 6 , 9, 10), although absence of A pM2 from these lesions 
has been reported as well (4). Therefore, A pM0 may be 
the predominant species deposited in CA (4, 5, 9—11). 
Similar to CA and classic senile plaques, AP in DA was 
reported to contain both Ap ,.40 and A p ,.42/43 (5). CA also 
contains the N-terminal truncated Ap peptides starting at 
residues 11 or 17 (8). However, data irom Down syn­
drome patients of different ages indicated that, whereas 
A p,..42/43 deposition precedes A pM0 depcsition in senile 
plaques, both isoforms seem to be deposited simulta­
neously in CA (11). The observation that CA is com­
posed of both AfJ^o and APM2/43 is confirmed by chem­
ical analysis of amyloid-containing vessels (12).
A number of familial AD cases have been linked to 
mutations either in the APP gene or in the presenilin
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(PS)-l or PS-2 genes. Similar to cases of sporadic AD, 
the initial and most abundant Ap species in these patients 
is A pM2/43 (6 , 9, 13, 14). Mutations at APP717 or in the 
PS-1 gene result in an increased A(3 burden in the brain 
(6 , 9, 13, 15), whereas in cases with mutations in the 
PS-2 gene or at APP670/671, the Ap deposition is compa­
rable to that in sporadic AD (9, 14). Furthermore, in all 
of these cases of familial AD, the severity and frequency 
of CA and its Ap composition were comparable to spo­
radic AD (6 , 9, 13, 14), indicating that neither mutation 
leads to a predisposition for CA. Apart form the above- 
mentioned HCHWA-D mutation at APP693, which leads 
to severe CA formation, another mutation at APP692 may 
also lead to increased formation of CA (16). Thus, it is 
remarkable that mutations within the A(3 region of APP 
predispose to CA, whereas mutations in APP flanking the 
Ap sequence do not lead to increased CA formation.
In conclusion, it is likely that in general ApM2/43 is the 
major component of diffuse senile plaques and that both 
APj.40 and A pM2/43 are deposited in classic senile plaques, 
CA, and DA (4, 6). The differential composition of Ap 
in CA and senile plaques and, more importantly, the dif­
ferences in timing of deposition of Ap species in these 
lesions suggest that the Ap in CA on the one hand, and 
in senile plaques on the other, is produced by distinct and 
probably independent mechanisms. This conclusion is 
supported by observations of cases with familial AD due 
to mutations in the PS-1 gene or at APP7l7. Due to these 
mutations the production of Ap,.^ is increased relative to 
APj.40 (17-19), and, accordingly, parenchymal A p ^  de­
position is also increased in these patients. However, this 
is not reflected in changes in the composition of CA, 
since A 0mo remains the predominant isoform in CA of 
these patients (9, 13), supporting differential effects of 
these mutations on the pathogenesis of either lesion.
A ¡3 Fibrillogenesis: Ap may exist in a soluble form as 
well as in a p-pleated sheet conformation (2 0 ), basically 
through the p-sheet structure of the residues 14-21 and 
29-39/42 (20). Ap ,_42 is less soluble and forms fibrils 
faster than shorter isoforms (21), which indicates that the 
C-terminal sequence of Ap is critical in the determination 
of the solubility of the peptide. The process of amyloid 
formation in vivo may be seeded or nucleated by trace 
amounts of amyloid fibrils (21). Progression of amyloid 
formation may involve the incorporation of potentially 
soluble Ap peptides that aggregate onto the initially 
formed seed. Since APM2 is relatively insoluble compared 
with APj.40, small seeds of A p ^  fibrils may grow rapidly 
by incorporation of ApM0, the isoform that is predomi­
nantly produced by cultured cells (19). Formation of the 
fibril seed is, then, the rate-limiting step of amyloidoge- 
nesis, an event that apparently does not occur in the dif­
fuse senile plaques of the cerebellar molecular layer be­
cause these plaques do not acquire A P ^  immunoreactivity 
or transform into classic senile plaques. Although this
“ seeding” theory sounds attractive, it cannot explain the 
differences in physical state of Ap between CA and dif­
fuse senile plaques. Whereas in the former lesion Ap 
mostly assembles into fibrils, in the latter, Ap is in a non­
aggregated form, despite the fact that both lesions contain 
ApM2/43. Therefore, A p ^ ^ is  not the only factor that de­
termines the assembly state of Ap. Other molecules po­
tentially involved in the formation of amyloid are the 
amyloidogenic non-Ap component of amyloid (NAC) 
(22) or Ap peptides modified by advanced glycation (23), 
but both these components are produced in CA as well 
as in senile plaques. Locally produced Ap-associated fac­
tors, produced either in the vasculature or in the brain 
parenchyma, may also affect Ap fibrillogenesis. The role 
of such factors will be discussed in paragraph 4.
Cells
Cellular Involvement in the Generation o f Senile 
Plaques and Congophilic Angiopathy: In situ hybridiza­
tion studies demonstrated that mRNA encoding for 
APP695 and APP751/770 was predominantly found in cortical 
pyramidal neurons (24) in both normal and AD brains, 
but not in glial or endothelial cells. Immunohistochemical 
staining of brain sections for APP confirmed that neurons 
of normal and AD brains, but not microglial cells or as­
trocytes, expressed APP (25). Furthermore, in classic se­
nile plaques, dystrophic neurites are APP positive (25, 
26). These data suggest that neurons are the primary pro­
ducers of APP in the brain parenchyma.
Clusters of activated microglial cells, indicative of an 
inflammatory response, are associated with classic senile 
plaques (27, 28). Given the absence of microglial APP 
expression, it is possible that they have a secondary func­
tion, e.g. in processing Ap into fibrils (29). Alternatively, 
their expression of Fc and complement receptors (30), 
and of a marker indicative of an enhanced lysosomal ac­
tivity (31), suggests that they function as phagocytes and 
remove Ap (32). An increased astrocyte reactivity can 
also be observed around senile plaques, probably follow­
ing microglial activation (28).
In summary, it is likely that neurons are the major 
candidates for the production of APP and Ap in senile 
plaques, whereas microglial cells and astrocytes may 
have an accessory function in senile plaque formation. 
Activated glial cells are presumably involved in gener­
ating an inflammatory response to Ap production that 
may contribute to the formation of amyloid-containing 
classic senile plaques and to neuronal pathology (see be­
low) (reviewed in [33]). The observations that cerebellar 
diffuse senile plaques are not accompanied by activated 
microglial and astrocytic cells (31, 34) and that these 
plaques do not mature into classic senile plaques and lack 
neuronal pathology support this view.
The production of Ap in CA is likely mediated by 
different cell types. It has been suggested that Ap fibrils
J Neuropathol Exp Neurol, Vo I 56, July, 1997
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There are indications that, depending on the degree of 
deposition, CA may lead to vascular malfunctioning. In 
contrast to the relatively mild CA in the majority of AD 
brains, patients with sporadic and severe CA may occa­
sionally suffer from cerebral hemorrhages due to vessel 
rupture. In these advanced stages of CA, an increase or 
activation of monocyte/macrophage lineage cells is ob­
served that, in exceptional cases, may lead to granulo­
matous angiitis (45).
Cellular Degeneration in Senile Plaques and in Con- 
gophilic Angiopathy: The presence of neuronal degener­
ation in AD brains is represented by the formation of 
intraneuronal NFTs and dystrophic neurites. Several stud­
ies have indicated that neuronal degeneration may be re­
lated to the presence of Ap, but this molecule may also 
exert protective effects on neuronal cells: soluble Ap, 
added in low doses to cultures of freshly isolated neurons, 
may enhance the rate of survival (46). However, reports 
describing a toxic effect of A(3 on neuronal cells are more 
numerous. Injection of isolated human amyloid cores 
containing aggregated Ap or synthetic AfJ into rat brains 
induced neurodegeneration (47), which indicates that the 
peptide has a direct toxic effect. When administered to 
cultured neurons, Ap peptides, especially when aggre­
gated, induced neurotoxicity, loss of presynaptic termi­
nals, and the development of dystrophic neurites (48, 49). 
The neurotoxic effect of pre-aggregated or soluble A(3 
could be blocked by the amyloid-binding dye Congo red 
(48), which is probably based on the inhibition of fibril 
formation or binding to preformed fibrils. These in vitro 
data on Ap-mediated neuronal toxicity correlate well 
with the pathology in the AD brain. Diffuse senile 
plaques that are composed of nonfibrillar Ap lack any 
sign of neuronal degeneration, whereas in classic senile 
plaques, A (3 fibrils and neurodegenerative changes coin­
cide.
A(3 may also cause neurodegeneration via indirect 
pathways. Neuronal ceil death may be mediated by for­
mation of the complement membrane attack complex 
(C5b-9), which has been demonstrated in dystrophic neu­
rites and neuropil threads (50). Furthermore, Ap may 
stimulate microglial cells to produce neurotoxic sub­
stances, such as cytokines, proteases, and free radicals 
(51). Also, astrocytes may contribute to neuronal damage 
by producing growth inhibitory compounds that impair 
neurite outgrowth (52).
An important feature of CA is the degeneration of cells 
of the vascular wall. Several ultrastructural or imrnuno- 
histochemical studies have demonstrated that endothelial 
cells, pericytes and smooth muscle cells (43, 53, 54) un­
dergo degeneration in amyloid-laden vessels. Sharply in 
contrast with the effects of synthetic Ap peptijdes on neu­
rons are the effects on cultured vascular cells. Whereas 
degeneration of cultured neurons can be induced by dif­





Control 8.39 ±  1.37 3.20 ±  2.17
APi_4o 2.22 ±  1.10 2.32 ±  1.08
HCHWA-D Ap,_4o 34.20 ±  21.35 20.48 ± 1 .1 9
Congo red 6.06 ±  4.84 0.21 ±  0.36
HCHWA-D A(3,„40
Congo red 6.48 ±  4.24 0.25 ±  0.43
Effect of incubation for 6 days with 25 jjlM nonaggregated 
synthetic HCHWA-D A(3,_4iJ and of Congo red on the viability 
of cultured human brain pericytes and smooth muscle cells (per­
centage of dead cells of triplicate incubations [mean ±  SD]). 
Reproduced from (41) with permission.
when aggregated, only A pM2—but not A pM0—caused 
degeneration of cultured leptomeningeal smooth muscle 
cells and pericytes (38, 41). Moreover, only soluble Ap 
was found to induce these effects, and pre-aggregation of 
the peptide completely abolished its effects (55). A re­
markable inversed effect was observed when synthetic 
AP peptides carrying the HCHWA-D mutation were ap­
plied to these cells in vitro. A robust degenerating effect 
on cultured smooth muscle cells and pericytes was ob­
served with HCHWA-D A pM0, but not with HCHWA-D 
APi.42 (41, 56). This effect could be inhibited by Congo 
red (41) (Table 1), which suggests that Ap assembly is a 
common mechanism in the destructive effects of Ap on 
both vascular cells and neurons. The effects of AP pep­
tides carrying the HCHWA-D mutation on cultured neu­
rons have not been studied.
In summary, these studies indicate that the mechanisms 
that lead to the degeneration of either neuronal or vas­
cular cells may be essentially different and depend on the 
chemical and physical state of Ap, which implies that the 
cellular pathology observed in senile plaques and CA 
may have an independent etiology. Moreover, inflam­
matory reactions mediated by microglial cells may sig­
nificantly contribute to the neuronal damage, whereas 
vascular degeneration in AD usually proceeds in the vir­
tual absence of an inflammatory response. The severe 
vascular pathology of HCHWA-D can at least in part be 
explained by the profound degenerating effects of 
HCHWA-D A pM0 on smooth muscle cells and pericytes, 
although inflammatory mechanisms may have an addi­
tional effect on these cells in HCHWA-D brains.
Ap-associated Proteins in Senile Plaques and in 
Congophilic Angiopathy
Apart from Ap itself, several Ap-associated proteins 
have been identified in senile plaques (see Table 2). Al­
though many more proteins have been identified than 
those mentioned here, this review only focuses on those
J  Neuropathol Exp Neurol, Voi 56, July, 1997
TABLE 2
DIFFERENCES BETWEEN THE PATHOGENESIS OF SP AND CA IN AD 7 5 5
Aß-associated Components in Various Aß-containing Lesions in AD Brains
Component
Cerebral cortex 
Diffuse SP Classic SP
Cerebellar cortex 
Diffuse SP Classic SP CA DA References
Complement factors
C lq + ± + + ND (59, 62, 63, 70, 78, 79)
C3d + + + ND ND (59, 62, 63, 70)
C4c + + + + + ND (59, 62, 78, 79)
C4bp + + + ND (50, 62, 63, 78, 79)
Clusterin + — + ND ND (50, 62)
Vitronectin + + ND ND ND ND (50)
Acute phase proteins
oer ACT + + + ± + (60, 61, 63, 70)
a2-macroglobulin + — + — ND (61, 62)
Amyloid P + + - t - + + ND (62-64, 70)
Miscellaneous
IC AM - 1 + — + — + (65, 68)
HSPG m 1 » » ja i — + " b ND (57, 69)
ApoE + + + + + ND (58, 62)
APP — + 1 — ND + ND (26, 37)
NAC + + ND ND ND (22)
The presence (4*) or absence ( - )  of expression is listed. When conflicting data have been described, a (± )  is indicated. See 
text for details. SP: senile plaques; CA: congophilic angiopathy, cerebrovascular amyloidosis; DA: dyshoric angiopathy; C4bp: 
C4-binding protein; a r ACT: a,-antichymotrypsine; ICAM-1 : intercellular adhesion molecule-1; HSPG: heparan sulfate proteo­
glycan; ApoE: apolipoprotein E; APP: amyloid precursor protein; NAC: non-Ap component of amyloid.
1 Localized in dystrophic neurites.
components that have been studied in more than one re­
port or in different Ap-containing lesions. These factors 
include heparan sulfate proteoglycan (HSPG) (57), ApoE 
(58), and several inflammatory proteins, which include 
the complement factors Clq, C3, C4 (59), the comple­
ment inhibitors C4-binding protein (C4bp), clusterin 
(ApoJ) and vitronectin (50), the acute phase proteins a,- 
antichymotrypsin (a r ACT) (60, 61) and amyloid P com­
ponent (62-64), and the cytokine-inducible adhesion 
molecule ICAM-1 (65) (Fig. 2). The presence of all these 
components has been unequivocally demonstrated in cor­
tical diffuse and classic senile plaques. Also, in cortical 
brain sections from young Down syndrome and 
HCHWA-D patients, where usually no classic senile 
plaques are found, a,-ACT, complement factors and 
HSPG can be found (66, 67). The acute phase protein a 2- 
macroglobulin is only found in classic senile plaques, 
whereas APP is expressed in dystrophic neurites in this 
plaque type (26, 61, 62).
Only a limited number of the above-mentioned factors 
are expressed in cerebellar diffuse senile plaques. In these 
lesions ApoE has been detected (62), but we did not ob­
serve ICAM-1 expression in these lesions (68) (Fig. 2). 
HSPG, clusterin and a 2-macroglobulin were also absent 
(62, 69). Reports about early complement factors, a,- 
ACT and amyloid P component are conflicting (62, 63, 
70), which probably indicates that their expression is low
or depends on the pathological state of the tissue. Re­
markably, we observed that ICAM-1 is expressed in the 
rare classic senile plaques of the granular or Purkinje cell 
layers of the cerebellum (68). Other groups also reported 
expression of HSPG and a2-macroglobulin in these clas­
sic senile plaques (62, 69).
An explanation for the absence of several A(3-associated 
factors from cerebellar diffuse senile plaques may be that 
they are produced during the transformation of diffuse se­
nile plaques into classic senile plaques and may affect this 
transformation process. The production of A(3-associated 
components may be determined by the ceil populations of 
specific brain regions, e.g. the cerebral cortex vs the cere­
bellum. Neuronal or glial cells may have a different vul­
nerability to Ap and a differential capacity to produce Afi- 
associated factors, and there may be diminished interactions 
between glial and neuronal cells in the cerebellum due to 
lower cell numbers compared with the cerebral cortex. Al­
though the Ap of diffuse senile plaques is in a relatively 
“soluble” form, it is not cleared from the brain parenchy­
ma, which indicates that it is retained in the neuropil via 
binding to other factors. Several of the Ap-associated fac­
tors, such as ApoE, a r ACT, Clq, clusterin, and HSPG, can 
bind to Ap (71—75). The Ap-associated components ar  
ACT, ApoE (76), Clq (73) and HSPG (77) may accelerate 
Ap fibril formation, as was observed under various exper­
imental conditions. However, the Ap-associated protein
I Neuropathol Exp Neuroi, Vol 56, July, 1997
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Fig. 4. A  model for a different pathogenesis of cerebrovascular amyloidosis and senile plaques. Altered APP metabolism  
leads to the production of nonfibrillar Af3 by vascular cells and neurons. Mutations at APP692 or APP693 may lead to increased 
vascular A(3 production, and mutations in the PS-1 gene or at APP717 may lead to increased parenchymal A (3 production. In the 
brain parenchyma, nonfibrillar A (3 gradually transforms into fibrils, a process that is probably affected by Ap-associated proteins 
and an acute phase reaction. The involvement of Ap-associated proteins and of ECM components in the formation of Ap fibrils 
in CA is less clear. Ap fibrils cause neuronal degeneration. Non-fibrillar Ap is toxic to smooth muscle cells/pericytes, but a role 
for aggregated Ap in this process cannot be entirely excluded. The formation of Ap fibrils leads to the activation of glial cells 
that may be engaged in Ap fibril formation or removal. According to this model, formation of DA follows CA. formation. SMC: 
smooth muscle cells; APP: amyloid precursor protein; Ap: amyloid p protein; ECM: extracellular matrix; CA: cerebrovascular 
amyloidosis (congophilic angiopathy); DA: dyshoric angiopathy; PS: presenilin; FAD: familial Alzheimer disease.
exception of rare cases of vasculitis—evoked only in the 
latter lesion, which contributes significantly to a different 
pathogenesis of either lesion. The observations on DA 
clearly illustrate this different response to amyloid be­
cause inflammatory products are only generated when the 
vascular amyloid penetrates the brain parenchyma. Al­
though pericytes and smooth muscle cells are able to pro­
duce inflammatory reaction products such as ICAM-1 
(40) and a r ACT (our unpublished observations), they do 
not deposit these factors in CA. The physical state of Ap 
in senile plaques may be affected by a number of inflam­
matory proteins. Other factors, such as basement mem­
brane components, may affect Ap fibrillogenesis in CA, 
whereas ApoE and HSPG may be involved in A3 fibril 
formation in both senile plaques and CA.
CONCLUDING REMARKS
In this review we summarized data from studies in 
which a variety of analytical approaches were used to 
demonstrate that the structure, composition and patho­
genesis of CA is different from that of senile plaques. 
The differences in Ap isoforms that constitute the lesions, 
the effects of mutations in the APP or PS genes, the ex­
pression of Ap-associated factors, the cell types involved
in Ap production, and the mechanisms of AP-mediated 
cellular degeneration all indicate that the pathogenesis of 
CA is different from that of senile plaques (Fig. 4). One 
of the central issues that leads us to speculate that CA 
and senile plaques have a different pathogenesis is that 
during the formation of classic senile plaques an inflam­
matory reaction is generated that may play a significant 
role in the formation of Ap fibrils, whereas this does not 
occur in CA. Since these fibrils are toxic to neurons, in** 
flammatory reactions contribute to neuronal degeneration 
by direct and indirect mechanisms. In contrast, the rela­
tive absence of such reactions in CA and the lack of 
toxicity of Ap fibrils for vascular cells point towards al­
ternative cytotoxic mechanisms in the vasculature. Here, 
our in vitro data and that of others fit in to suggest that 
it is the non-fibrillar form of Ap that directly causes vas­
cular degeneration, independent of inflammatory reac­
tions or Ap fibril formation.
The pathogenesis of CA has received little attention in 
the past, as CA was thought to be a pathological lesion 
of minor importance in the AD brain. However, the ar­
guments summarized in this review warrant a more de­
tailed investigation of its pathogenesis. The impact of CA 
in AD brains may extend beyond vascular pathology
J  Neuropat hoi Exp Neurol, Vo I 56, July, 1997
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only. Endothelial cells and, to a lesser extent, pericytes, 
are involved in maintaining the blood-brain barrier (87). 
Degeneration of these cells in vessels affected by CA 
may lead to an impaired functioning of the blood-brain 
barrier in AD patients, which contributes to a disrupted 
microcirculation and energy supply to the brain (88), 
which, in turn, will have profound effects on brain me­
tabolism in general.
It will be very important to study suitable and physi­
ologically relevant cell culture models that include hu­
man cerebral glial and neuronal cells on the one hand 
and vascular cells on the other hand to study the specific 
processes that lead to senile plaque or CA formation, re- 
spectively, in order to gain more insight into the patho- 
biology of AD. Furthermore, transgenic mice specifically 
developed to study the pathogenesis of CA rather than 
senile plaques will provide more insight into the specific 
mechanisms of CA formation and into its impact on brain 
metabolism. Since the contribution of CA to the devel­
opment of dementia and its effect on the formation of 
senile plaques are barely understood, such future studies 
may unravel the significance of CA for AD.
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